SỰ CHỈ RÕ

Over the next five years, nearly 200 blockbusters will lose patent protection, unlocking a $300 billion market opportunity.‌Drugs like ‌pembrolizumab, semaglutide, and apixaban‌—each generating over $1 billion annually—are approaching the “patent cliff.” This shift will reshape the pharmaceutical landscape, challenging generic drug companies to move beyond the traditional “copy, launch, profit” model. Success will now depend on ‌technical capability, supply chain strategy, and long-term vision‌, with competition ultimately centering on the foundation of all drugs: ‌active pharmaceutical ingredients (APIs)‌.

1.API Process Innovation: Building an Unsurpassable Technological Moat

If API process innovation addresses the question of “whether it can be done,” then the API-formulation integration strategy answers the proposition of “how to do it better.” Integrated layout is becoming a strategic choice for generic drug companies to enhance the clinical value of their products and respond to national centralized procurement policies.

2.‌API-Formulation Integration: From Cost Advantage to Clinical Value

If API process innovation addresses the question of “whether it can be done,” then the API-formulation integration strategy answers the proposition of “how to do it better.” Integrated layout is becoming a strategic choice for generic drug companies to enhance clinical value and respond to national centralized procurement policies.

3.‌Securing the High-End API Supply Chain: From Product Competition to Ecosystem Rivalry

Generic drug competition is intensifying, shifting from standalone product rivalry to comprehensive battles between supply chains and ecosystems. Securing control over the high-end active pharmaceutical ingredient (API) supply chain has become a decisive factor in gaining market advantage.

Over the next five years, there is good reason to believe that companies establishing core capabilities in high-purity API manufacturing, complex formulation technologies, and international compliance standards will not only capture a share of the $300 billion market, but also reshape the global generic drug industry landscape. When “generic” is imbued with technological depth and innovative value, the path forward for the industry may become significantly broader.